MoonLake Immunotherapeutics MLTX Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's available-for-sale debt securities - amortized cost?
- MoonLake Immunotherapeutics (MLTX) reported available-for-sale debt securities - amortized cost of $59.07M in Q1 2026.
- How has MoonLake Immunotherapeutics's available-for-sale debt securities - amortized cost changed year-over-year?
- MoonLake Immunotherapeutics's available-for-sale debt securities - amortized cost decreased by 71.3% year-over-year, from $205.91M to $59.07M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.